A Phase III Clinical Trial to Study the Efficacy & Safety of MK-8931 (SCH900931) in subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
Clinical Trial Grant
Administered By
Neurology, Behavioral Neurology
Awarded By
Merck Sharp & Dohme
Start Date
June 1, 2016
End Date
May 30, 2019
Administered By
Neurology, Behavioral Neurology
Awarded By
Merck Sharp & Dohme
Start Date
June 1, 2016
End Date
May 30, 2019